학술논문

REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers
Document Type
article
Source
Movement Disorders. 30(13)
Subject
Biomedical and Clinical Sciences
Ophthalmology and Optometry
Brain Disorders
Neurosciences
Aging
Parkinson's Disease
Neurodegenerative
Sleep Research
Clinical Research
Neurological
Adult
Aged
Female
Glutamine
Humans
Judaism
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Male
Middle Aged
Mutation
Parkinson Disease
Protein Serine-Threonine Kinases
Serine
Sleep Deprivation
Surveys and Questionnaires
Parkinson's disease
LRRK2
REM Behavior Disorder
RBDSQ
preclinical
AJ LRRK2 Consortium
Clinical Sciences
Human Movement and Sports Sciences
Neurology & Neurosurgery
Clinical sciences
Language
Abstract
BackgroundRapid eye movement sleep behavior disorder occurs with idiopathic Parkinson's disease (PD) and often precedes PD. Its frequency in LRRK2-PD and utility as a preclinical marker has not been established.MethodsOne hundred forty-four idiopathic PD, 142 LRRK2 G2019S mutation PD, 117 non-manifesting carriers, 93 related noncarriers, and 40 healthy controls completed the Rapid eye movement sleep Behavior Disorder Screening Questionnaire.ResultsCut scores were met by 30.6% idiopathic PD, 19.7% LRRK2-PD, 6% nonmanifesting carriers, 20.4% related noncarriers, and 15% controls. The likelihood of abnormal scores was decreased in LRRK2-PD versus idiopathic PD (odds ratio = 0.55, P = 0.03), nonmanifesting carriers versus related noncarriers (OR = 0.25, P < 0.01), and PD of less than 3 years' duration, 1 of 19 LRRK2-PD versus 14 of 41 idiopathic PD (P < 0.05).ConclusionsA lower frequency of abnormal questionnaire scores is seen in LRRK2-PD, especially in early LRRK2-PD, and in nonmanifesting carriers. Therefore, the Rapid eye movement sleep Behavior Disorder Questionnaire is unlikely to serve as a preclinical marker for phenoconversion to PD.